Preliminary results of a phase I trial inspire the phase II KarMMa study of bb2121, an anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor (CAR) T Cell therapy, for relapsed and refractory Multiple Myeloma (rrMM)

被引：0
|
作者：
Einsele, H. [1 ]
Goldschmidt, H. [2 ]
Weisel, K. [3 ]
Hege, K. [4 ]
Munshi, N. [5 ]
San Miguel, J. [6 ]
机构：
[1] Univ Clin Wuerzburg, Wurzburg, Germany
[2] Univ Clin Heidelberg, Heidelberg, Germany
[3] Univ Clin Tuebingen, Tubingen, Germany
[4] Celgene Corp, San Francisco, CA USA
[5] Dana Farber Canc Inst, Boston, MA 02115 USA
[6] Clin Univ Navarra, Pamplona, Spain
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V409
引用
收藏
页码：134 / 134
页数：1
相关论文
共 50 条
  • [21] Updated Health-Related Quality of Life Results from the KarMMa Clinical Study in Patients with Relapsed and Refractory Multiple Myeloma Treated with the BCell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy Idecabtagene Vicleucel (idecel, bb2121)
    Delforge, Michel
    Shah, Nina
    Rodriguez-Otero, Paula
    Braverman, Julia
    Dhanda, Devender
    Shi, Ling
    Guo, Shien
    Yu, Peiwen
    Liao, Weiqin
    Campbell, Timothy B.
    Munshi, Nikhil C.
    BLOOD, 2021, 138
  • [22] BCMA-targeting chimeric antigen receptor T cell therapy for relapsed and/or refractory multiple myeloma
    Fang, Jiamin
    Zhou, Fuling
    ANNALS OF HEMATOLOGY, 2024, 103 (04) : 1069 - 1083
  • [23] KarMMa-3: A Phase 3 Study of Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy Vs Standard Regimens in Relapsed and Refractory Multiple Myeloma
    Delforge, Michel
    Baz, Rachid C.
    Cavo, Michele
    Callander, Natalie S.
    Ghobadi, Armin
    Rodriguez-Otero, Paula
    Mateos, Maria-Victoria
    Massaro, Monica
    Ding, Li
    Patel, Payal
    Pittari, Gianfranco
    Novick, Steven
    Giralt, Sergio A.
    Berdeja, Jesus G.
    BLOOD, 2020, 136
  • [24] Idecabtagene Vicleucel (ide-cel, bb2121), a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy: Qualitative Analyses of Post Treatment Interviews (Months 6-24) for Patients with Relapsed and Refractory Multiple Myeloma in the Karmma Clinical Trial
    Shah, Nina
    Delforge, Michel
    Rodriguez-Otero, Paula
    Moshkovich, Olga
    Braverman, Julia
    Dhanda, Devender
    Lanar, Sally
    Devien, Jennifer
    Miera, Matthew
    Gerould, Heather
    Campbell, Timothy B.
    Munshi, Nikhil C.
    BLOOD, 2021, 138
  • [25] Cost-Effectiveness of Anti-BCMA Chimeric Antigen Receptor T Cell Therapy in Relapsed/Refractory Multiple Myeloma
    Yamamoto, Chihiro
    Minakata, Daisuke
    Yokoyama, Daizo
    Furuki, Shuka
    Noguchi, Atsuto
    Koyama, Shunsuke
    Oyama, Takashi
    Murahashi, Rui
    Nakashima, Hirotomo
    Ikeda, Takashi
    Kawaguchi, Shin-ichiro
    Hyodo, Kazuki
    Toda, Yumiko
    Ito, Shoko
    Nagayama, Takashi
    Umino, Kento
    Morita, Kaoru
    Ashizawa, Masahiro
    Ueda, Masuzu
    Hatano, Kaoru
    Sato, Kazuya
    Ohmine, Ken
    Fujiwara, Shin-ichiro
    Kanda, Yoshinobu
    TRANSPLANTATION AND CELLULAR THERAPY, 2024, 30 (01): : 118.e1 - 118.e15
  • [26] A phase I study of anti-BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
    Li, Chunrui
    Cao, Wenyue
    Que, Yimei
    Wang, Qiuxiang
    Xiao, Yi
    Gu, Chaojiang
    Wang, Di
    Wang, Jue
    Jiang, Lijun
    Xu, Hao
    Xu, Jinhuan
    Zhou, Xiaoxi
    Hong, Zhenya
    Wang, Na
    Huang, Liang
    Zhang, Shangkun
    Chen, Liting
    Mao, Xia
    Xiao, Min
    Zhang, Wei
    Meng, Li
    Cao, Yang
    Zhang, Tongcun
    Li, Jian
    Zhou, Jianfeng
    CLINICAL AND TRANSLATIONAL MEDICINE, 2021, 11 (03):
  • [27] Durable Clinical Responses in Heavily Pretreated Patients with Relapsed/Refractory Multiple Myeloma: Updated Results from a Multicenter Study of bb2121 Anti-Bcma CAR T Cell Therapy
    Berdeja, Jesus G.
    Lin, Yi
    Raje, Noopur
    Munshi, Nikhil
    Siegel, David
    Liedtke, Michaela
    Jagannath, Sundar
    Maus, Marcela V.
    Turka, Ashley
    Lam, Lyh Ping
    Hege, Kristen
    Morgan, Richard A.
    Quigley, Michael Travis
    Kochenderfer, James N.
    BLOOD, 2017, 130
  • [28] IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T CELL THERAPY: QUALITATIVE ANALYSES OF EARLY POST-TREATMENT INTERVIEWS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) PATIENTS IN THE KARMMA CLINICAL TRIAL
    Braverman, J.
    Dhanda, D. S.
    Moshkovich, O.
    Lanar, S.
    Miera, M.
    Williams, A. E.
    Murphy, R.
    Devlen, J.
    Hege, K.
    Campbell, T. B.
    VALUE IN HEALTH, 2021, 24 : S61 - S61
  • [29] Updated results from CARTITUDE-1: Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T (CAR-T) cell therapy, in relapsed/refractory multiple myeloma (RRMM)
    Jagannath, Sundar
    Berdeja, Jesus G.
    Jakubowiak, Andrzej
    Agha, Mounzer
    Cohen, Adam
    Madduri, Deepu
    Hari, Parameswaran
    Yeh, Tzu-Min
    Olyslager, Yunsi
    Banerjee, Arnob
    Jackson, Carolyn C.
    Allred, Alicia
    Zudaire, Enrique
    Deraedt, William
    Wu, Xiaoling
    Pacaud, Lida
    Akram, Muhammad
    Lin, Yi
    Martin, Thomas
    Usmani, Saad Z.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S15 - S16
  • [30] Results from the KarMMa clinical trial: Secondary Quality-of-Life domains in patients (pts) with relapsed and refractory multiple myeloma (RRMM) treated with the BCMA-directed CAR T cell therapy Idecabtagene Vicleucel (ide-cel; bb2121)
    Einsele, H.
    Shah, N.
    Delforge, M.
    San-Miguel, J. F.
    Bertin, K. B.
    Tahir, M. J.
    Lewis, H. B.
    Wang, J.
    Braverman, J.
    Campbell, T. B.
    Dhanda, D.
    Munshi, N. C.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 206 - 208
12345